Cyclo(-RGDfK)

TargetMol
Product Code: TAR-T6812
Supplier: TargetMol
CodeSizePrice
TAR-T6812-2mg2mg£115.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6812-5mg5mg£151.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6812-1mL1 mL * 10 mM (in DMSO)£193.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6812-10mg10mg£216.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6812-25mg25mg£345.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6812-50mg50mg£511.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6812-100mg100mg£585.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Cyclo (-RGDfK) is an effective and specific αvβ3 integrin inhibitor.
CAS:
161552-03-0
Formula:
C27H41N9O7
Molecular Weight:
603.681
Pathway:
Cytoskeletal Signaling
Purity:
0.9983
SMILES:
NCCCC[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O
Target:
Integrin

References

Dai XD, et al. Tetrahedron Letters. 2000, 41(33), 6295?6298. Jin ZH, et al. Mol Cancer. 2007, 6(41), 1-9. Roy S, Spinali K, Schmuck E G, et al. Cardiac fibroblast derived matrix-educated macrophages express VEGF and IL-6, and recruit mesenchymal stromal cells[J]. Journal of Immunology and Regenerative Medicine. 2020, 10: 100033. Zhou D, et al. J Control Release. 2013, 169(3), 204-210. Lopez-Rodriguez V, et al. Preparation and preclinical evaluation of (66)Ga-DOTA-E(c(RGDfK))2 as a potential theranostic radiopharmaceutical. Nucl Med Biol. 2015 Feb;42(2):109-14. Vilchis-Ju?rez A, et al. J Biomed Nanotechnol. 2014 Mar;10(3):393-404. Sancey L, et al. Mol Ther. 2009, 17(5), 837-843.